Loading...

FITC anti-human IFN-γ Antibody

Pricing & Availability
Clone
4S.B3 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_4SB3_FITC_063009.jpg
PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with mouse IgG1 FITC isotype control and CD3 (UCHT1) APC
  • A_4SB3_FITC_063009.jpg
    PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with mouse IgG1 FITC isotype control and CD3 (UCHT1) APC
  • B_4SB3_FITC_063009.jpg
    PMA/ionomycin-stimulated (6 hours) human peripheral blood lymphocytes stained with 4S.B3 FITC and CD3 (UCHT1) APC
See FITC spectral data
Cat # Size Price Save
502505 25 tests ¥20,680
502507 50 µg ¥27,280
502506 100 tests ¥49,060
Description

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Partially purified, native human IFN-γ
Formulation
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
µg sizes: 0.5 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.
Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.
Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.
Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut)
  2. Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut)
  3. Sester M, et al. 2002. J. Virol. 76:3748. (ICFC)
  4. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC)
  5. Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA)
  6. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
  7. Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC)
  8. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
  9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)
Product Citations
  1. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  2. Morimoto Y, et al. 2018. Immunity. 49:134. PubMed
  3. Meraviglia S, et al. 2017. Oncoimmunology. 6:e1347742. PubMed
  4. Kuranda K, et al. 2018. J Clin Invest. 128:5267. PubMed
  5. Yu J, et al. 2019. Oncol Lett. 17:1461. PubMed
  6. Zuazo M, et al. 2019. EMBO Mol Med. 11(7). PubMed
  7. Shokri MR, et al. 2019. Sci Rep. 9:10007. PubMed
  8. Vacaflores A, et al. 2017. Mol Immunol. 81:1. PubMed
  9. Stein RG, et al. 2019. Cancer Res. 79:1507. PubMed
  10. Poulsen L 2012. J Immunol. 189:4431. PubMed
  11. Spencer A, et al. 2014. PLoS One. 9:100538. PubMed
  12. Rochman Y, et al. 2015. PLoS One. 10:122198. PubMed
  13. Lu T, et al. 2016. PLoS One. 11: 0148044. PubMed
  14. Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed
  15. Kessler B, et al. 2017. Sci Rep. 7:42791. PubMed
  16. Fisher J, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.03.002. PubMed
  17. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  18. Pierce CA, et al. 2020. Sci Transl Med. 12:00. PubMed
  19. Zhou Y, et al. 2020. Cell Rep. 31:107574. PubMed
  20. Preglej T, et al. 2020. JCI Insight. 5(4):. PubMed
  21. Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed
  22. Hamilton JR, et al. 2021. Cell Reports. 35(9):109207. PubMed
  23. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  24. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  25. Zou F, et al. 2021. Mol Ther. 29:1794. PubMed
  26. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  27. Carre C, et al. 2021. iScience. 24:102970. PubMed
  28. Priyanto H, et al. 2021. J Clin Tuberc Other Mycobact Dis. 22:100214. PubMed
  29. Hirschberger S, et al. 2022. Front Med (Lausanne). 9:923502. PubMed
  30. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  31. Olafsdottir TA, et al. 2022. Commun Biol. 5:914. PubMed
  32. Lu H, et al. 2020. Am J Reprod Immunol. 83:. PubMed
  33. Lo Presti E, et al. 2020. J Leukoc Biol. 108:749. PubMed
  34. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
  35. Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed
  36. Zhang H, et al. 2023. Nat Immunol. 24:96. PubMed
  37. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  38. Du Q, et al. 2022. J Virol. 96:e0095922. PubMed
RRID
AB_315230 (BioLegend Cat. No. 502505)
AB_315232 (BioLegend Cat. No. 502507)
AB_315231 (BioLegend Cat. No. 502506)

Antigen Details

Structure
Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID
3458 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account